Lista de obras - G. C. Cook - Dominio Público Uruguay

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma

artículo científico publicado en 2014

A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function

artículo científico publicado en 2014

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma ⬇️

artículo científico publicado en 2015

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

artículo científico publicado en 2017

An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics

scientific article published on 14 October 2020

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma

artículo científico publicado en 2015

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

artículo científico publicado en 2015

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ⬇️

artículo científico publicado en 2016

Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.

artículo científico publicado en 2014

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

scientific article published on 22 August 2019

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

artículo científico publicado en 2015

Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

artículo científico publicado en 2020

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

artículo científico publicado en 2020

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

scholarly article by Athanasios Dimopoulos et al published 20 September 2018 in Haematologica

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

scientific article published on 03 November 2020

Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network

scientific article published on 18 June 2020

Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy

artículo científico publicado en 2015

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

artículo científico publicado en 2020

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

artículo científico publicado en 2016

Evolution or revolution in multiple myeloma therapy and the role of the UK

artículo científico publicado en 2020

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplant ⬇️

artículo científico publicado en 2016

Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.

artículo científico publicado en 2014

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

artículo científico publicado en 2020

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

scientific article published on 22 May 2020

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

artículo científico publicado en 2013

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

artículo científico publicado en 2015

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

artículo científico publicado en 2015

Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study

artículo científico publicado en 2017

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

artículo científico publicado en 2015

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

scientific article published on 12 July 2020

Optimizing the management of patients with spinal myeloma disease.

artículo científico publicado en 2015

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

artículo científico publicado en 2014

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

artículo científico publicado en 2016

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. ⬇️

artículo científico publicado en 2017

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

artículo científico publicado en 2018

Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.

artículo científico publicado en 2015

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy

scientific article published on 21 May 2020

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.

artículo científico publicado en 2015

Reply to M. Roschewski et al.

artículo científico publicado en 2014

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

artículo científico publicado en 2022

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. ⬇️

artículo científico publicado en 2016

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. ⬇️

artículo científico publicado en 2016

The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines

artículo científico publicado en 2016

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial ⬇️

artículo científico publicado en 2016

The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.

artículo científico publicado en 2014

Time to redefine Myeloma

artículo científico publicado en 2015

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

artículo científico publicado en 2016

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years

artículo científico publicado en 2014

United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.

artículo científico publicado en 2014

Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord

artículo científico publicado en 2015

Updates to the guidelines for the diagnosis and management of multiple myeloma

artículo científico publicado en 2014

Lista de obras de G. C. Cook

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma

A retrospective multi-centre study of the effects of allogeneic haematopoietic SCT on pulmonary function

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma ⬇️

Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.

An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ⬇️

Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.

Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Defining the vulnerable patient with myeloma-a frailty position paper of the European Myeloma Network

Downregulation of myeloma-induced ICOS-L and regulatory T cell generation by lenalidomide and dexamethasone therapy

Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Evolution or revolution in multiple myeloma therapy and the role of the UK

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplant ⬇️

Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

Optimizing the management of patients with spinal myeloma disease.

Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. ⬇️

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents.

Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with Multiple Myeloma receiving systemic anti-cancer therapy

Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols.

Reply to M. Roschewski et al.

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. ⬇️

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial. ⬇️

The "Next Big Thing" in Treatment for Relapsed or Refractory Multiple Myeloma May Be Held Back by Design-Between the Lines

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial ⬇️

The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party.

Time to redefine Myeloma

Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years

United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma.

Unrelated Cord Blood Transplantation in adults: evolution, experience and long-term outcomes in the UK National Health Service : a retrospective analysis on behalf of the British Society of Blood and Marrow Transplantation and Eurocord

Updates to the guidelines for the diagnosis and management of multiple myeloma